Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-15T01:46:28.479Z Has data issue: false hasContentIssue false
  • English
  • Français

Stelazine (Trifluoperazine) A Preliminary Report on a Clinical Trial

Published online by Cambridge University Press:  08 February 2018

J. R. A. Madgwick ,
Desmond L. M. McNeill ,
Marie Driver  and
George C. Preston
J. R. A. Madgwick
Affiliation:
Long Grove Hospital, Epsom, Surrey
Desmond L. M. McNeill
Affiliation:
Long Grove Hospital, Epsom, Surrey
Marie Driver
Affiliation:
Long Grove Hospital, Epsom, Surrey
George C. Preston
Affiliation:
Long Grove Hospital, Epsom, Surrey
Get access Rights & Permissions [Opens in a new window]

Extract

Trifluoperazine, which is 2-trifluoromethyl-10-(3′-[1″-methylpiperazinyl-4″]-propyl)-phenothiazine dihydrochloride—a preparation manufactured by Smith, Kline and French Laboratories Limited under the description SKF5019—is the most recent phenothiazine derivative reported to have a beneficial effect on certain types of mental illness. On the basis of animal tests trifluoperazine is described as having nine times the potency of chlorpromazine in blocking the conditioned response, and its specificity is greater than that of chlorpromazine.

Type
Original Articles
Information
Journal of Mental Science , Volume 104 , Issue 437 , October 1958 , pp. 1195 - 1198
Copyright
Copyright © Royal College of Psychiatrists, 1958 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Rudy, L. H., et al., Amer. J. Psych., 1958, 114, 747.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.